Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

BackgroundSeveral studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 study of pembrolizumab monotherapy for previously treated recurrent or metastatic cancer, high TMB as assessed by the FoundationOn...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal for immunotherapy of cancer Ročník 10; číslo 1; s. e003091
Hlavní autoři:	Cristescu, Razvan, Aurora-Garg, Deepti, Albright, Andrew, Xu, Lei, Liu, Xiao Qiao, Loboda, Andrey, Lang, Lixin, Jin, Fan, Rubin, Eric H, Snyder, Alexandra, Lunceford, Jared
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England BMJ Publishing Group Ltd 01.01.2022 BMJ Publishing Group LTD BMJ Publishing Group
Edice:	Original research
Témata:	Aged Antibodies, Monoclonal, Humanized - therapeutic use B7-H1 Antigen - metabolism Biomarkers, Tumor - genetics Cancer Cell death Chemotherapy FDA approval Female Gene expression Genomes Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Immunotherapy Biomarkers Laboratories Lung cancer Male Melanoma Metastasis Microsatellite Instability Monoclonal antibodies Mutation Neoplasms - drug therapy Neoplasms - genetics Neoplasms - metabolism programmed cell death 1 receptor Regulatory approval Retrospective Studies Targeted cancer therapy Treatment Outcome tumor biomarkers Tumors Whole Exome Sequencing United States > US Massachusetts California programmed cell death 1 receptor tumor biomarkers immunotherapy
ISSN:	2051-1426, 2051-1426
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!